Nektar Therapeutics Ownership | Who Owns Nektar Therapeutics?

Overview Forecast RevenueFinancials Chart Transcripts

Nektar Therapeutics Ownership Summary

Nektar Therapeutics is owned by 36.70% institutional investors, 0.62% insiders, and 62.68% retail investors. Bvf inc/il is the largest institutional shareholder, holding 9.06% of NKTR shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.57% of its assets in Nektar Therapeutics shares.

NKTR Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Nektar Therapeutics	36.70%	0.62%	62.68%
Sector	Healthcare Stocks	232.01%	10.74%	-142.75%
Industry	Biotech Stocks	381.47%	10.55%	-292.02%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Bvf inc/il	1.28M	9.06%	$72.64M
Blackrock	15.16M	7.78%	$18.79M
Vanguard group	1.03M	7.29%	$43.43M
Farallon capital management	791.00K	5.62%	$45.01M
Two seas capital lp	745.18K	5.29%	$31.51M
Blackrock funding, inc. /de	645.61K	4.58%	$27.30M
Morgan stanley	566.42K	4.02%	$23.95M
Prosight management, lp	554.63K	3.94%	$23.45M
Two sigma investments, lp	434.24K	3.08%	$24.71M
Emerald advisers	384.34K	2.73%	$16.25M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Great point partners	300.00K	7.04%	$17.07M
22nw, lp	331.12K	5.89%	$14.00M
Prosight management, lp	554.63K	4.85%	$23.45M
Stonepine capital management	85.00K	3.93%	$4.84M
Propel bio management	82.82K	2.99%	$3.50M
Bvf inc/il	1.28M	2.94%	$72.64M
Superstring capital management lp	51.27K	2.87%	$2.92M
Deuterium capital management	37.35K	2.29%	$1.58M
Boxer capital management	125.00K	2.27%	$7.11M
Monashee investment management	94.13K	2.24%	$3.98M

Top Buyers

Holder	Shares	% Assets	Change
Blackrock	15.16M	0.00%	9.28M
Altium capital management lp	3.00M	0.79%	2.99M
Bvf inc/il	1.28M	2.94%	1.28M
Farallon capital management	791.00K	0.18%	791.00K
Two seas capital lp	745.18K	0.65%	745.18K

Top Sellers

Holder	Shares	% Assets	Change
Samlyn capital	-	-	-9.67M
Eventide asset management	-	-	-6.65M
Almitas capital	-	-	-4.61M
Jacobs levy equity management	-	-	-3.01M
Millennium management	2.29M	0.00%	-2.24M

New Positions

Holder	Shares	% Assets	Change	Value
Bvf inc/il	1.28M	2.94%	1.28M	$72.64M
Farallon capital management	791.00K	0.18%	791.00K	$45.01M
Two seas capital lp	745.18K	0.65%	745.18K	$31.51M
Prosight management, lp	554.63K	4.85%	554.63K	$23.45M
Great point partners	300.00K	7.04%	300.00K	$17.07M

Sold Out

Holder	Change
Salomon & ludwin	-3.00
Cornerstone planning group	-5.00
Clearstead advisors	-5.00
United community bank	-7.00
Montag a & associates	-7.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2025	68	-57.23%	5,169,695	-64.12%	36	0.35%	44	-59.26%	14	-48.15%
Sep 30, 2025	37	-66.36%	1,954,060	-74.48%	13	0.47%	24	-17.24%	6	-91.67%
Jun 30, 2025	37	-77.30%	2,048,084	-98.35%	14	0.42%	10	-86.49%	27	-44.90%
Mar 31, 2025	8	-94.59%	15,114,671	-88.63%	7	0.18%	2	-97.14%	4	-88.89%
Dec 31, 2024	137	-2.84%	129,034,595	-8.31%	61	1.36%	64	6.67%	33	-8.33%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Eventide Healthcare & Life Sciences I	6.65M	3.57%	-
Vanguard US Total Market Shares ETF	5.72M	3.08%	-
iShares Russell 2000 ETF	4.62M	2.48%	-
Vanguard Total Stock Mkt Idx Inv	594.51K	2.12%	-
iShares Russell 2000 Value ETF	1.66M	0.89%	-
Vanguard Institutional Extnd Mkt Idx Tr	220.26K	0.79%	-222.00
Fidelity Small Cap Index	1.83M	0.70%	-
Invesco Main Street Small Cap R6	179.41K	0.64%	78.72K
Invesco Small Cap Core	179.41K	0.64%	179.41K
PRIMECAP Odyssey Aggressive Growth	178.72K	0.64%	-3.10K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Feb 18, 2026	Zalevsky Jonathan	Chief R&D Officer	Sell	$13.14K
Feb 18, 2026	ROBIN HOWARD W	President & CEO	Sell	$30.88K
Jan 20, 2026	Zalevsky Jonathan	Chief R&D Officer	Sell	$137.94K
Nov 25, 2025	Zalevsky Jonathan	Chief R&D Officer	Sell	$62.80K
Nov 25, 2025	Wilson Mark Andrew	Chief Legal Officer	Sell	$34.20K

Insider Transactions Trends

Date	Buy	Sell
2026 Q1	-	3
2025 Q4	-	3
2025 Q3	-	20
2025 Q2	-	3
2025 Q1	-	3

NKTR Ownership FAQ

Who Owns Nektar Therapeutics?

Nektar Therapeutics shareholders are primarily institutional investors at 36.70%, followed by 0.62% insiders and 62.68% retail investors. The average institutional ownership in Nektar Therapeutics's industry, Biotech Stocks , is 381.47%, which Nektar Therapeutics falls below.

Who owns the most shares of Nektar Therapeutics?

Nektar Therapeutics’s largest shareholders are Bvf inc/il (1.28M shares, 9.06%), Blackrock (15.16M shares, 7.78%), and Vanguard group (1.03M shares, 7.29%). Together, they hold 24.14% of Nektar Therapeutics’s total shares outstanding.

Does Blackrock own Nektar Therapeutics?

Yes, BlackRock owns 7.78% of Nektar Therapeutics, totaling 15.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 18.79M$. In the last quarter, BlackRock increased its holdings by 9.28M shares, a 157.82% change.

Who is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested?

Great point partners is Nektar Therapeutics’s biggest shareholder by percentage of total assets invested, with 7.04% of its assets in 300K Nektar Therapeutics shares, valued at 17.07M$.

Who is the top mutual fund holder of Nektar Therapeutics shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Nektar Therapeutics shares, with 3.57% of its total shares outstanding invested in 6.65M Nektar Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools